TRIO-US B-12 (TALENT)

Breast - TALENT

TRIO-US B-12 (TALENT)

Objective

A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of trastuzumab deruxtecan (DS-8201a) with or without anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting

Principal Investigator(s)
David Chan, MD

Clinical Trial Categories

  • UCLA Trio Clinical Trials